Sat, Jul 26, 2014, 9:43 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Peregrine Pharmaceuticals, Inc. Message Board

  • bobradcliff77777 bobradcliff77777 Feb 19, 2013 11:55 AM Flag

    Bavituximab, finally a drug that works with the immune system to recognize and fight the tumor

    This is not only a new drug, but a new Paradigm.

    About Bavituximab

    Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in eight clinical trials, including three randomized Phase II trials in front-line and second-line non-small cell lung cancer and front-line pancreatic cancer, and five investigator-sponsored trials (ISTs) in additional oncology indications. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

    Sentiment: Hold

 
PPHM
1.55-0.03(-1.90%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.